Patents by Inventor Mark E. Hayes
Mark E. Hayes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240325525Abstract: The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.Type: ApplicationFiled: May 24, 2024Publication date: October 3, 2024Applicant: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes, Alexander Koshkaryev, Ross B. Fulton
-
Publication number: 20240309291Abstract: The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.Type: ApplicationFiled: May 24, 2024Publication date: September 19, 2024Applicant: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes
-
Patent number: 12077383Abstract: A pharmacy system and methodology for individually packaged medications and/or supplements assembled into an order for each patient which can be delivered to a long-term care facility or other institution for patient consumption. The process may include receiving a patient's prescription order, automatically dispensing packaged unit doses, and assembling into individually packaged bags for each patient. Various safeguards and measures built into this system and method increase patient safety, eliminate waste, and increase labor efficiency by reducing and/or minimizing the disposal of unused medications and supplements.Type: GrantFiled: September 18, 2020Date of Patent: September 3, 2024Assignee: REMEDI TECHNOLOGY HOLDINGS, LLCInventors: Kimberly Hawkes, Steven E. Schneider, Mark Stielau, Richard W Snodgrass, Thomas P. Hayes
-
Patent number: 12077725Abstract: The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.Type: GrantFiled: December 12, 2022Date of Patent: September 3, 2024Assignee: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes
-
Patent number: 12070471Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).Type: GrantFiled: February 17, 2023Date of Patent: August 27, 2024Assignee: CELATOR PHARMACEUTICALS, INC.Inventors: Mark E Hayes, Charles O. Noble, Francis C. Szoka
-
Patent number: 12064479Abstract: The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.Type: GrantFiled: May 25, 2023Date of Patent: August 20, 2024Assignee: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes, Alexander Koshkaryev, Ross B. Fulton
-
Patent number: 12059497Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.Type: GrantFiled: March 22, 2021Date of Patent: August 13, 2024Assignee: Ipsen Biopharm Ltd.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
-
Publication number: 20230390317Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).Type: ApplicationFiled: February 17, 2023Publication date: December 7, 2023Inventors: Mark E. HAYES, Charles O. NOBEL, Francis C. SZOKA
-
Publication number: 20230381303Abstract: The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.Type: ApplicationFiled: May 25, 2023Publication date: November 30, 2023Applicant: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes, Alexander Koshkaryev, Ross B. Fulton
-
Publication number: 20230126953Abstract: The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.Type: ApplicationFiled: December 12, 2022Publication date: April 27, 2023Applicant: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes
-
Patent number: 11591544Abstract: The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.Type: GrantFiled: November 24, 2021Date of Patent: February 28, 2023Assignee: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes
-
Patent number: 11583544Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).Type: GrantFiled: December 24, 2019Date of Patent: February 21, 2023Assignee: CELATOR PHARMACEUTICALS, INC.Inventors: Mark E. Hayes, Charles O. Noble, Francis C. Szoka
-
Publication number: 20220411394Abstract: The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.Type: ApplicationFiled: August 8, 2022Publication date: December 29, 2022Applicant: Akagera Medicines, Inc.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes, Alexander Koshkaryev, Ross B. Fulton
-
Publication number: 20220162521Abstract: The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.Type: ApplicationFiled: November 24, 2021Publication date: May 26, 2022Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes
-
Publication number: 20210205219Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.Type: ApplicationFiled: March 22, 2021Publication date: July 8, 2021Applicant: Ipsen Biopharm Ltd.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
-
Publication number: 20210008091Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).Type: ApplicationFiled: December 24, 2019Publication date: January 14, 2021Inventors: Mark E. HAYES, Charles O. NOBLE, Francis C. SZOKA
-
Patent number: 10722467Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).Type: GrantFiled: June 27, 2019Date of Patent: July 28, 2020Assignee: ZONEONE PHARMA, INC.Inventors: Mark E. Hayes, Charles O. Noble, Francis C. Szoka, Jr.
-
Patent number: 10507182Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).Type: GrantFiled: September 10, 2018Date of Patent: December 17, 2019Assignee: ZONEONE PHARMA, INC.Inventors: Mark E. Hayes, Charles O. Noble, Francis C. Szoka, Jr.
-
Publication number: 20190314282Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).Type: ApplicationFiled: June 27, 2019Publication date: October 17, 2019Inventors: Mark E. HAYES, Charles O. NOBLE, Francis C. SZOKA, JR.
-
Publication number: 20190110991Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).Type: ApplicationFiled: September 10, 2018Publication date: April 18, 2019Inventors: Mark E. HAYES, Charles O. NOBLE, Francis C. SZOKA, JR.